Annals of Oncology 15:786-792, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients
Received 22 September 2003; revised 13 January 2004; accepted 20 January 2004Background:
We describe 16 months’ single-institution experience with gefitinib (‘Iressa’, ZD1839) used as ‘ultimum refugium’ for pretreated non-small-cell lung cancer (NSCLC) patients.
Patients and methods:
Toxicity, response and survival data of NSCLC patients participating in a compassionate-use program with gefitinib were reviewed. Documented disease progression and confirmation of the absence of other treatment options were requested. Oral gefitinib at a dose of 250 mg/day was given until disease progression, unacceptable toxicity or death. Cox’s proportional hazards model was used to analyze relationships between factors and probability of survival.
Results:
Rapid disease precluded treatment in eight cases. Of 92 evaluable patients, one-third had a baseline performance status (PS) of 
2. The main side-effects of gefitinib were grade 1–2 diarrhea and skin rash. A disease control rate of 46% (objective response rate 8.7%) and 1-year survival of 29% were documented. Histology (adenocarcinoma) and a ‘never-smoking’ history were predictive of response. Number of previous chemotherapy regimens, gender, time since diagnosis and time since last chemotherapy lacked such an association. Radiotherapy during gefitinib treatment was well tolerated and was associated with prolonged survival in a patient with multiple brain metastases. Multivariate analyses revealed a significant impact of PS on survival. A ‘never-smoking’ history, adenocarcinoma/bronchoalveolar-cell carcinoma and female gender showed a trend towards better survival outcomes.
Conclusion:
Gefitinib’s single-agent activity in a group consisting of pretreated NSCLC patients is confirmed. Side-effects of gefitinib were mild. Prolonged survival was associated with good PS and less significantly with a never-smoking history, female gender and histology. Additional studies on mechanisms of tumor control and selection of target populations for this remarkable new drug are warranted.
Departments of 1 Thoracic Oncology and 2 Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Key words: non-small-cell lung cancer, NSCLC, gefitinib, Iressa, EGRA – tyrosine kinase inhibitor, ZD183g, bronchoalveolar-cell carcinoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Eberhard, G. Giaccone, and B. E. Johnson Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting J. Clin. Oncol., February 20, 2008; 26(6): 983 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N van Zandwijk and M. van de Vijver clairvoyance or reliable prediction of the future? Ann. Onc., March 1, 2007; 18(3): 407 - 408. [Full Text] [PDF]
|
|
|
|
 |
|
 R. van Puijenbroek, L. Bosquee, A-P. Meert, D. Schallier, J-C. Goeminne, G. Tits, P. Collard, K. Nackaerts, J-L. Canon, F. Duplaquet, et al. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study Eur. Respir. J., January 1, 2007; 29(1): 128 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N van Zandwijk, A Mathy, L Boerrigter, H Ruijter, I Tielen, D de Jong, P Baas, S Burgers, and P Nederlof EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer Ann. Onc., January 1, 2007; 18(1): 99 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Janne and B. E. Johnson Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res., July 15, 2006; 12(14): 4416s - 4420s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Calvo and J. Baselga Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors J. Clin. Oncol., May 10, 2006; 24(14): 2158 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shimato, T. Mitsudomi, T. Kosaka, Y. Yatabe, T. Wakabayashi, M. Mizuno, N. Nakahara, H. Hatano, A. Natsume, D. Ishii, et al. EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib Neuro-oncol, April 1, 2006; 8(2): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, S. Harita, K. Gemba, T. Yonei, A. Bessho, and M. Tanimoto Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience Ann. Onc., November 1, 2005; 16(11): 1817 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Janne, J. A. Engelman, and B. E. Johnson Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology J. Clin. Oncol., May 10, 2005; 23(14): 3227 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Mohamed, S. Ramalingam, Y. Lin, W. Gooding, and C. P. Belani Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer Ann. Onc., May 1, 2005; 16(5): 780 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-S. Kim, J.-Y. Jeong, Y.-C. Kim, K.-J. Na, Y.-H. Kim, S.-J. Ahn, S.-M. Baek, C.-S. Park, C.-M. Park, Y.-I. Kim, et al. Predictors of the Response to Gefitinib in Refractory Non-Small Cell Lung Cancer Clin. Cancer Res., March 15, 2005; 11(6): 2244 - 2251. [Abstract] [Full Text] [PDF]
|
|